Patents by Inventor Flavio Maina

Flavio Maina has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD AND KIT FOR DIAGNOSING AND FOR TREATMENT OF A CANCER BASED ON THE OVEREXPRESSION OF THE ADAMTSL5 GENE
    Publication number: 20260110687
    Abstract: The method for treating a cancer in a mammal in need thereof includes collecting a biological sample from said mammal; determining, from said biological sample, if the ADAMTSL5 gene is overexpressed; diagnosing a cancer from the determination of the overexpression of the gene; and administering to the mammal an effective amount of a pharmaceutical composition including an agent or agents targeting ADAMTSL5 or the ADAMTSL5 pathway, and a pharmaceutically acceptable carrier, where the composition comprises an inhibitor of ADAMTLS5 and is adapted to reducing overexpression of ADAMTSL5 in the mammal.
    Type: Application
    Filed: December 9, 2025
    Publication date: April 23, 2026
    Applicants: UNIVERSITE D'AIX-MARSEILLE (AMU), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Flavio Maina, Maria Arechederra, Rosanna Dono, Timothy Mead, Suneel Apte
  • METHOD AND KIT FOR DIAGNOSING AND FOR TREATMENT OF A CANCER BASED ON THE OVEREXPRESSION OF THE ADAMTSL5 GENE
    Publication number: 20210123916
    Abstract: The invention relates to a method for diagnosing a cancer in a mammal in a need thereof. The method comprises the following steps: collecting a biological sample from said mammal; determining, from said biological sample, if the ADAMTSL5 gene is overexpressed; diagnosing a cancer from the determination of the overexpression of said gene. It also relates to a kit for determining an overexpression of the ADAMTSL5 gene in a biological sample obtained from a mammal, to a pharmaceutical composition comprising an agent targeting ADAMTSL5 or the ADAMTSL5 pathway as well as a pharmaceutically acceptable carrier for use in the treatment of a cancer, and to a use of an ADAMTSL5 mRNA or protein as a biomarker of cancer.
    Type: Application
    Filed: March 29, 2019
    Publication date: April 29, 2021
    Applicants: UNIVERSITE D'AIX-MARSEILLE (AMU), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Flavio Maina, Maria Arechederra, Rosanna Dono, Timothy Mead, Suneel Apte
  • Aminoacid derivatives, their process of preparation and their therapeutical uses as inhibitors of oncogenic signals by the Met family
    Patent number: 8822698
    Abstract: Novel amino acids derivatives, in particular some amino acid amides derivatives, their process of preparation and their use for inhibiting Met-triggered disorders, in particular cancer.
    Type: Grant
    Filed: November 28, 2012
    Date of Patent: September 2, 2014
    Assignees: Universite d'Aix-Marseille, Universite de Lorraine, Oreste Piccolo Studio di Consulenza Scientifica, Universitat de Barcelona, Centre National de la Recherche Scientifique (C.N.R.S.)
    Inventors: Flavio Maina, Rosanna Dono, Oreste Piccolo, Daniele Passarella, Francesco Colombo, Joan Bosch, Bernard Maigret, Vincent Leroux
  • REGULATION OF GLYPICAN 4 ACTIVITY TO MODULATE THE FATE OF STEM CELLS AND USES THEREOF
    Publication number: 20130164268
    Abstract: The present invention thus relates to stem cells or progenitor cells wherein the expression and/or activity of a member of the glypican family is reduced or abolished for use for the treatment of a pathological condition selected from the group consisting of a degenerative disease, a cardiac disorder, a metabolic disease and an injury by stem cell-based therapy.
    Type: Application
    Filed: July 29, 2011
    Publication date: June 27, 2013
    Applicant: UNIVERSITE DE LA MEDITERRANEE AIX-MARSEILLE II
    Inventors: Rosanna Dono, Annalisa Fico, Flavio Maina